Do Wall Street Analysts Like AbbVie Stock?

Core Insights - AbbVie Inc. is a research-based biopharmaceutical company with a market cap of $385.2 billion, focusing on innovative medicines across various therapeutic areas [1] Performance Overview - Over the past 52 weeks, AbbVie shares have increased by 6.6%, underperforming the S&P 500 Index, which rose by 17.7%. However, year-to-date, AbbVie stock is up 22.1%, outperforming the S&P 500's 16.3% increase [2] - AbbVie has also outperformed the iShares U.S. Healthcare ETF, which saw a 2.9% decline over the past 52 weeks and a 4.4% increase year-to-date [3] Financial Results - AbbVie reported Q3 earnings on October 31, with a 9.1% year-over-year revenue growth to $15.8 billion, exceeding consensus estimates by 1.2%. Adjusted EPS fell 38% year-over-year to $1.86 but surpassed analyst expectations of $1.77 [4] - The company raised its fiscal 2025 adjusted EPS guidance to a range of $10.61 to $10.65, despite a 4.5% drop in shares following the earnings report, attributed to a $1.50-per-share impact from acquired R&D and milestone expenses [4] Analyst Expectations - For the current fiscal year ending in December, analysts project AbbVie's EPS to grow by 4.6% year-over-year to $10.58. AbbVie has consistently surpassed consensus estimates in the last four quarters [5] - The consensus rating among 28 analysts is a "Moderate Buy," with 15 "Strong Buy," 2 "Moderate Buy," and 11 "Hold" ratings [5] Analyst Ratings and Price Target - The analyst configuration has slightly shifted, with 16 analysts now suggesting a "Strong Buy" rating. On November 3, JPMorgan Chase & Co. maintained an "Overweight" rating on AbbVie and raised its price target to $260, indicating a potential upside of 22.2% from current levels [6]